▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Dec 5, 2013 by Todd Campbell

How Europe's Compassion for Hepatitis C Patients Helps Bristol-Myers

The European Medicines Agency has granted compassionate use for Bristol-Myers Squibb's daclatasvir, a promising hepatitis C drug currently seeking approval in Japan, for use with Gilead's sofosbuvir.

Dec 5, 2013 by Todd Campbell

Johnson & Johnson Battles St. Jude for Cardiac Mapping Leadership

Johnson & Johnson's and St. Jude's turf war for dominance in treating atrial fibrillation is shifting to next-generation technologies. This is creating opportunities for certain companies as market demand climbs.

Dec 4, 2013 by Todd Campbell

How St. Jude Hopes to Cut Into Medtronic's Pacemaker Dominance

A wave of innovation is hitting the implantable pacemaker industry, which could have game-changing implications for Medtronic, St. Jude, and Boston Scientific.

Dec 3, 2013 by Todd Campbell

Here's How St. Jude Hopes to Win in the Atrial Fibrillation Market

One of the fastest growing areas in cardiac treatment is atrial fibrillation. That growth is capturing the attention of major medical device companies like St. Jude (STJ), who are eagerly acquiring next generation technology.

Dec 2, 2013 by Todd Campbell

How Mylan Is Turning the Table on Teva

Teva (TEVA) is losing patent protection for its multi-billion dollar blockbuster Copaxone next year, opening the door for Mylan (MYL) to win market share with its generic version.

Dec 2, 2013 by Todd Campbell

Merck Faces Off Against Bristol-Myers' Yervoy

A compelling new drug in development from Merck (MRK) has a chance to change melanoma treatment, posing a threat to rapidly growing market share for Bristol Myers' (BMY) Yervoy.

Nov 30, 2013 by Todd Campbell

CVS Reaches Deeper into Patient Care

A $2.1 billion investment from CVS catapults it into the leading provider of infusion drug services for patients; better positioning it against competitors Walgreen (WAG) and Rite-Aid (RAD).

Nov 27, 2013 by Todd Campbell

Why Pay Royalties? Just Buy the Whole Company

Bayer would rather pay $2.4 billion for all of Algeta than shell out payments for its Xofiga prostate cancer drug.

Nov 27, 2013 by Todd Campbell

Better Buy: Teva, Mylan, or Actavis?

More patent expirations ahead mean greater sales growth for these three generic drugmakers.

Nov 26, 2013 by Todd Campbell

Better Buy: CVS, Express Scripts, or Catamaran?

Aging boomers, Medicaid expansion, and insurance reform may mean more sales for the three major pharmacy benefit managers.

Nov 26, 2013 by Todd Campbell

Is BioMarin's Vimizim Grabbing Suitors Attention?

Drug companies continue to acquire orphan drug biotechnology companies to boost pipelines. Will BioMarin's Vimizim help convince them to buy BioMarin too?

Nov 26, 2013 by Todd Campbell

Biogen's Tecfidera Time-Out Pays Off

A decision to put off the launch of Biogen's (BIIB) highly anticipated launch of its MS drug Tecfidera in Europe appears to have paid off, thanks to expanded patent protection.

Nov 26, 2013 by Todd Campbell

Can Hill-Rom Succeed Against Stryker?

Can acquisitions and buybacks help Hill-Rom's medical equipment business pull ahead of its main rival?

Nov 25, 2013 by Todd Campbell

Can Clinics Move the Needle for CVS, Walgreen, and Wal-Mart?

Retail clinics are becoming more popular as consumers look for low cost, just-in-time health care. With the Affordable Care Act expanding insurance coverage for millions, will retail clinics become profit centers for CVS, Walgreen, and Wal-Mart?

Nov 25, 2013 by Todd Campbell

Can United Therapeutics Survive Against New Competitors?

New drug approvals from Bayer and Actelion threaten United Therapeutics' leadership in treating pulmonary arterial hypertension. Can the company maintain its market share and reward investors?

Nov 24, 2013 by Todd Campbell

Better Buy: Merck, Pfizer, or Johnson & Johnson?

Merck, Pfizer and Johnson & Johnson are among the biggest global drug manufacturers. Each faces threats from generic competitors. But is one a better buy than the other?

Nov 20, 2013 by Todd Campbell

Teva's High Hopes for Custirsen

Teva is losing patent protection on its multi billion cancer drug Copaxone in 2015 and that has the company increasingly reliant on its pipeline. The company expects Phase 3 data early next year for Custirsen, a prostate drug it hopes will offset some of Copaxone's expected sales drop.

Nov 18, 2013 by Todd Campbell

Celgene's Revlimid Faces a Tough Sell

In cost-conscious countries, even existing therapies face an uphill battle in winning approval for new indications. With new data behind it, Celgene hopes it can overcome cost concerns to win approval for Revlimid as a first-line treatment.

Nov 18, 2013 by Todd Campbell

Has Myeloma Met Its Match in Amgen's Kyprolis?

Amgen's high profile acquisition of Onyx Pharmaceuticals gave it Kyprolis, an existing multiple myeloma treatment with an opportunity to expand beyond its current indication.

Nov 17, 2013 by Todd Campbell

Are Doctors Shifting From Johnson & Johnson's Zytiga to Medivation's Xtandi?

Rapid sequential growth in sales of Medivation's Xtandi may suggest that it's gaining momentum against Johnson & Johnson's star drug Ztiga in prostate cancer.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services